Feb 05, 2018 11:11 am EST Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
Jan 16, 2018 7:00 am EST Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
Dec 13, 2017 8:00 am EST Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
Nov 29, 2017 7:00 am EST Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
Nov 15, 2017 12:00 pm EST Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy
Nov 08, 2017 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program
Nov 01, 2017 4:30 pm EDT Capricor Therapeutics Third Quarter 2017 Update Webcast and Conference Call Scheduled for Wednesday, November 8
Oct 25, 2017 7:00 am EDT Capricor Announces 12-Month Results from HOPE-1 Trial in Duchenne Muscular Dystrophy to be Presented at AHA Late-Breaking Session
Oct 06, 2017 9:00 am EDT Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy